Overview

Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)

Status:
Unknown status
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
Intravitreal injections of pegaptanib will induce the regression of Proliferative Diabetic Retinopathy (PDR) and reduce the need for retinal photocoagulation.
Phase:
Phase 4
Details
Lead Sponsor:
Valley Retina Institute
Collaborator:
Pfizer